Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Induction of broad, durable immune responses is a challenge in HIV vaccine development. HVTN 100 Part A administered subtype C-containing ALVAC-HIV at months 0 and 1, and ALVAC-HIV with bivalent subtype C gp120/MF59 at months 3, 6 and 12. As IgG binding antibody and T-cell responses were similar or...

Full description

Saved in:
Bibliographic Details
Main Authors: Vimla Naicker, Fatima Laher, Linda-Gail Bekker, Kelly E Seaton, Mary Allen, Stephen De Rosa, Nicole L Yates, Nonhlanhla N Mkhize, Kevin Saunders, Jack Heptinstall, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Chenchen Yu, Tandile Modise, Valerie Bekker, Nicole Grunenberg, Briana Furch, Maurine D Miner, Sanjay Phogat, Carlos A Diazgranados, Sanjay Gurunathan, Marguerite Koutsoukos, Olivier Van Der Meeren, Alison C Roxby, Guido Ferrari, Lynn Morris, David Montefiori, M Juliana McElrath, Georgia D Tomaras, Zoe Moodie
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLOS Global Public Health
Online Access:https://doi.org/10.1371/journal.pgph.0003319
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pgph.0003319

Similar Items